Business Description
Calliditas Therapeutics AB
ISIN : SE0010441584
Compare
Compare
Traded in other countries / regions
CALTX.SwedenLC8.Germany0A5R.UKCALT.USA IPO Date
2020-05-18Description
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.06 | |||||
| Debt-to-Equity | 9.44 | |||||
| Debt-to-EBITDA | -2.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 4.82 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 957.8 | |||||
| 3-Year EBITDA Growth Rate | 13.5 | |||||
| 3-Year EPS without NRI Growth Rate | -2 | |||||
| 3-Year FCF Growth Rate | -6.6 | |||||
| 3-Year Book Growth Rate | -36.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 56.25 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.81 | |||||
| 9-Day RSI | 51.37 | |||||
| 14-Day RSI | 52.08 | |||||
| 6-1 Month Momentum % | 85.21 | |||||
| 12-1 Month Momentum % | 109.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | |||||
| Quick Ratio | 2.59 | |||||
| Cash Ratio | 1.86 | |||||
| Days Inventory | 86.19 | |||||
| Days Sales Outstanding | 39.35 | |||||
| Days Payable | 343.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | -2.53 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.46 | |||||
| Operating Margin % | -24.32 | |||||
| Net Margin % | -30 | |||||
| FCF Margin % | -15.17 | |||||
| ROE % | -169.32 | |||||
| ROA % | -27.88 | |||||
| ROIC % | -64.74 | |||||
| 3-Year ROIIC % | -20.27 | |||||
| ROC (Joel Greenblatt) % | -659.27 | |||||
| ROCE % | -27.01 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.86 | |||||
| PS Ratio | 6.91 | |||||
| PB Ratio | 104.3 | |||||
| EV-to-EBIT | -31.2 | |||||
| EV-to-Forward-EBIT | 9.98 | |||||
| EV-to-EBITDA | -31.2 | |||||
| EV-to-Forward-EBITDA | 9.98 | |||||
| EV-to-Revenue | 7.09 | |||||
| EV-to-Forward-Revenue | 3.63 | |||||
| EV-to-FCF | -46.35 | |||||
| Earnings Yield (Greenblatt) % | -3.21 | |||||
| FCF Yield % | -2.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Calliditas Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 140.969 | ||
| EPS (TTM) (€) | -0.779 | ||
| Beta | 0 | ||
| Volatility % | 102.58 | ||
| 14-Day RSI | 52.08 | ||
| 14-Day ATR (€) | 0.060152 | ||
| 20-Day SMA (€) | 17.8415 | ||
| 12-1 Month Momentum % | 109.05 | ||
| 52-Week Range (€) | 7.18 - 18.37 | ||
| Shares Outstanding (Mil) | 54.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Calliditas Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Calliditas Therapeutics AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Calliditas Therapeutics AB Frequently Asked Questions
What is Calliditas Therapeutics AB(FRA:LC8)'s stock price today?
The current price of FRA:LC8 is €17.83. The 52 week high of FRA:LC8 is €18.37 and 52 week low is €7.18.
When is next earnings date of Calliditas Therapeutics AB(FRA:LC8)?
The next earnings date of Calliditas Therapeutics AB(FRA:LC8) is 2025-02-20.
Does Calliditas Therapeutics AB(FRA:LC8) pay dividends? If so, how much?
Calliditas Therapeutics AB(FRA:LC8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers